Precision oncology only works when biomarker testing helps identify the right patients before launch, explains Boehringer ...

Patrick Mooney, CEO of SpyGlass Pharma, shares how insights from the cockpit have shaped his approach to leading an innovative biotech.

Nasdaq’s new $5 million MVLS rule raises delisting risk for micro-cap life sciences companies, making exchange choice an ...

Life Sciences M&A policies in the EU, Israel, and Singapore are shifting, creating new opportunities for drug developers, according to legal experts at Meritas.

On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, ...

Biotech’s old risk-sharing model is breaking down, forcing academia, investors, pharma, and healthcare systems to collaborate earlier to bring cures to patients.

Over the weekend, the Financial Times reported that AstraZeneca and Bristol Myers Squibb were exploring what would have been the largest pharmaceutical merger in history. The news sent AstraZeneca's ...

For decades, the Silicon Valley playbook has dominated the narrative of innovation: a brilliant founder hacks together a minimum viable product in a garage, pitches a traditional venture capital (VC) ...

Psychedelic research is entering a defining moment. Programs are advancing, data are emerging, and the field is learning in real time what works and what needs to evolve. Yet many foundational ...

Understanding how a drug affects a patient's ability to drive is a critical part of clinical safety evaluation and is often underestimated. Knowing whether your drug impairs driving, how long that ...

On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell ...